Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone add-on after failure of first-line lenvatinib-containing therapy in unresectable hepatocellular carcinoma
ChiCTR2500097995Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: progression-free survival, objective response rate and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
pirfenidonelenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500097995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097995.